long-term effects of glp-1 receptor agonists Mapping the effectiveness and risks The long-term cardiovascular safety and
Description
Do not use a GLP-1 agonist if you have had a serious allergic reactions to Wegovy (semaglutide), Zepbound (tirzepatide) or Saxenda (liraglutide) or any of the ingredients in these medications

These dramatic results led to FDA approval of semaglutide 2.4 mg for obesity in June 2021 under the name Wegovy ( [136] )

Genetic studies suggest that changes affecting GIP signaling may increase breast cancer risk, indicating that GLP-1 and GIP pathways could influence cancer development

[28] Pratt, E., Ma, X., Liu, R., Robins, D., Haupt, A., Coskun, T.,

Because they slow digestion, GLP-1 drugs may interact with some medications and make them not work as well
